Live Breaking News & Updates on Newly Diagnosed Acute Graft Versus Host Disease

Itolizumab was associated with high clinical response rates at Day 15 and 29​Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169​Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host diseaseLA JOLLA, Calif. (BUSINESS WIRE) $EQ #GVHD Equillium, Inc. ....

United States , John Koreth , Michael Moore , Eq Gvhd Equillium Inc , Harvard Medical School , International Blood Marrow Transplant Research , Exchange Commission , Ono Pharmaceutical Co Ltd , Equillium Inc , Head Of Corporate Communications , Dana Farber Cancer Institute , Tandem Meetings , American Society , Cellular Therapy , International Blood , Marrow Transplant , Final Safety , Efficacy Results , Open Label Study Evaluating Itolizumab , Novel Targeted , Newly Diagnosed Acute Graft Versus Host Disease , Oral Abstract , Graft Versus Host Disease , Biocon Limited , Private Securities Litigation Reform Act , Investor Relations Officer ,